MTF Biologics Names New Horizon Medical Solutions Exclusive Distributor of AmnioBand® Membrane for Post-Acute and Outpatient Markets

EDISON, N.J.--(BUSINESS WIRE)--May 21, 2026--

MTF Biologics, a global nonprofit leader in tissue-based solutions, today announced the appointment of New Horizon Medical Solutions (NHMS) as the exclusive distributor of AmnioBand ® Membrane to wound care specialists, podiatrists, and mobile care practitioners across the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521298687/en/

The agreement combines AmnioBand's peer-reviewed Level 1 clinical evidence base with NHMS's specialized provider network and hands-on field support, creating a distribution model purpose-built for the complex realities of outpatient and mobile wound care. Clinicians gain consistent allograft access, expert point-of-care support, and the confidence of broad payer coverage through commercial and Medicare health plans reaching more than 280 million Americans.

“Wound care specialists and podiatrists deserve a solution they can trust; one backed by real clinical evidence, consistent payer access, and an uncompromising standard for quality and safety. New Horizon Medical Solutions’ exclusive focus on this patient population and their depth of provider relationships make them the right partner to expand that access.” - Joe Yaccarino, President & Chief Executive Officer, MTF Biologics

NHMS was selected for its dedicated wound care model, which integrates clinical field teams, established provider relationships, and practice infrastructure specifically designed for wound care and podiatry settings. The company’s singular focus on this patient population enables a level of clinical support and practice integration that broad-line distributors cannot match.

“The wound care clinicians we work with are managing complex patients under real payer and documentation pressure. They need a tissue solution with the clinical evidence to support their treatment decisions and the coverage reliability to make it practice-viable. AmnioBand delivers both. Our exclusive relationship ensures our providers will have consistent allograft access, expert clinical support at the point of care, and a partner they can count on now and long term.” - Will Hall, Chief Executive Officer, New Horizon Medical Solutions

The agreement reflects MTF Biologics’ mission to save and heal lives by expanding patient access to evidence-supported tissue solutions and underscores NHMS’s commitment to equipping wound care providers with the clinical tools and practice support they need to deliver better outcomes.

KEY HIGHLIGHTS

About AmnioBand ®

AmnioBand ® Membrane is a bilayer amnion/chorion placental allograft processed under aseptic processing standards with rigorous quality testing. With access across more than 280 million Americans through commercial and Medicare health plans, AmnioBand offers wound care specialists broad coverage and practice efficiency across patient populations. Its clinical foundation includes peer-reviewed publications giving clinicians demonstrated outcomes across wound care applications.

For more information about MTF Biologics and New Horizon Medical Solutions, visit www.mtfbiologics.org and www.nhmedical.com.

About MTF Biologics

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. In partnership with organ and tissue recovery organizations, MTF Biologics provides exceptional services, resources, and expertise to donors and their families; tissue and organ transplant patients; and clinicians and scientists who advance patient care.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institut für Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe.

About New Horizon Medical Solutions

New Horizon Medical Solutions is a forward-thinking company specializing in advanced wound care technologies, committed to developing and delivering biologically derived human placental allograft products that meet the highest safety and performance standards. NHMS's product portfolio includes amniotic tissues, micro autologous skin grafting, and wound care devices for wound imaging and debridement for chronic wounds, surgical reconstruction, burns, and orthopedic procedures. Through evidence-based design and precision manufacturing, NHMS strives to enhance patient outcomes in clinical practice.

MTF Biologics and New Horizon Medical Solutions are collaborating to advance care provided by wound care specialists, podiatrists, and mobile care practitioners.

ISTANBUL (AP) — A Turkish court on Thursday issued a ruling that effectively removed the head of the country’s main opposition party by annulling a 2023 congress that elected him.

The move deals a serious blow to the beleaguered Republican People’s Party, or CHP, as it struggles under waves of legal cases targeting its members and elected officials.

An appeals court in Turkey’s capital Ankara declared the CHP congress that picked Ozgur Ozel as chairman to be null, ordering that he should be replaced by his predecessor, Kemal Kilicdaroglu.

Last year, a lower court ruled against claims of irregularities and misconduct surrounding Ozel’s election but Thursday’s decision overturned the original verdict.

The ruling led to frantic meetings at the CHP’s Ankara headquarters, further threatening the opposition’s chances of unseating President Recep Tayyip Erdogan after more than two decades in office. Large crowds gathered outside the office block and police erected barriers.

The next presidential election is due in 2028 but Erdogan can call for an early vote. His main challenger, the CHP mayor of Istanbul Ekrem Imamoglu, has been imprisoned since March last year and is currently on trial on corruption charges.

The appeals court's decision suspends Ozel and members of the party’s executive board from their duties. They will be “provisionally” replaced by Kilicdaroglu and those who held office before the November 2023 congress.

In comments to broadcaster TV100, Kilicdaroglu called for party members to remain calm. “Our party is a very large party and it will solve its own problems internally,” he said. The 77-year-old was removed following a 13-year tenure as leader, during which the CHP failed to win any national elections.

Ozel, meanwhile, attempted to rally supporters.

“I am not promising you a path to power through a rose garden,” he posted on X following the ruling. “I am promising you the ability to endure suffering but never surrender. I am promising you honor, dignity, courage and struggle!”

The CHP is expected to challenge Thursday’s ruling in the Supreme Court in the coming days.

Justice Minister Akin Gurlek, who oversaw several cases against the CHP in his former role as Istanbul’s chief prosecutor, described the court’s ruling as one that “reinforces our citizens’ trust in democracy.”

Many observers have said that the legal cases against the CHP — mostly centered on corruption allegations — are politically motivated and aimed at neutralizing the party ahead of the next election. The government, however, insists that Turkey’s courts are impartial and act independently of political pressure.

Erdogan has ruled Turkey, first as prime minister and then as president, since 2003. His electoral record suffered a serious blow in 2019 when the CHP seized control of several major cities in local elections. In Istanbul, Imamoglu emerged as a popular and charismatic figure that many felt could successfully topple Erdogan.

FILE - Republican People's Party or (CHP) leader Ozgur Ozel gestures to party members during his speech during a CHP convention, in Ankara, April 6, 2025. (AP Photo/Ali Unal, File)

FILE - Turkish CHP party leader and Nation Alliance's presidential candidate Kemal Kilicdaroglu, center, joins legislators elected to the Grand National Assembly of Turkey as they attend their first parliamentary session, in Ankara, Turkey, June 2, 2023. (AP Photo/Ali Unal, File)